Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959412 · ClinicalTrials.gov registry record · Phase 2
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT01959412 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 91 participants.
The verdict
NCT01959412, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
Interventions
- DRUG Indacaterol 27.5 mcg
- DRUG Indacaterol 37.5
- DRUG Indacaterol 55 mcg
- DRUG Indacaterol 75 mcg
- DRUG Indacaterol 150 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959412
The ClinicalTrials.gov registry entry for NCT01959412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Indacaterol 27.5 mcg is the first listed.
NCT01959412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959412 about?
NCT01959412 is a clinical study titled "Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma". The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
What is the current status of trial NCT01959412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2013-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01959412?
The interventions under investigation include: Indacaterol 27.5 mcg (DRUG), Indacaterol 37.5 (DRUG), Indacaterol 55 mcg (DRUG), Indacaterol 75 mcg (DRUG), Indacaterol 150 mcg (DRUG).
Who is sponsoring clinical trial NCT01959412?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.